Healthcare -
Biotechnology - NASDAQ - US
$ 0.28446
-5.18 %
$ 12.7 M
Market Cap
-0.28
P/E
1. INTRINSIC VALUE
Balance Sheet
HCW Biologics Inc.
| Current Assets | 6.4 M |
| Cash & Short-Term Investments | 3.6 M |
| Receivables | 1.54 M |
| Other Current Assets | 1.27 M |
| Non-Current Assets | 22.1 M |
| Long-Term Investments | 1.6 M |
| PP&E | 20.5 M |
| Other Non-Current Assets | 56.5 K |
| Current Liabilities | 8.75 M |
| Accounts Payable | 6.17 M |
| Short-Term Debt | 0 |
| Other Current Liabilities | 2.58 M |
| Non-Current Liabilities | 6.3 M |
| Long-Term Debt | 6.3 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
HCW Biologics Inc.
| Revenue | 2.84 M |
| Cost Of Revenue | 2.28 M |
| Gross Profit | 560 K |
| Operating Expenses | 26.3 M |
| Operating Income | -25.7 M |
| Other Expenses | -723 K |
| Net Income | -25 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
HCW Biologics Inc.
| Net Income | -25 M |
| Depreciation & Amortization | 1.14 M |
| Capital Expenditures | -6.2 M |
| Stock-Based Compensation | 1 M |
| Change in Working Capital | -4.64 M |
| Others | -160 K |
| Free Cash Flow | -28.7 M |
Wall Street Analysts Price Targets
HCW Biologics Inc.
HCWB has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
HCWB does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
HCW Biologics Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements
MIRAMAR, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (Nasdaq: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported that, on March 3, 2025, the Nasdaq Hearings Panel (the “Panel”) of The Nasdaq Stock Market LLC (“Nasdaq” or the “Exchange”) granted the Company an extension in which to regain compliance with all continued listing rules of The Nasdaq Capital Market.
globenewswire.com
- 4 weeks ago
HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial
MIRAMAR, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, today announced that it has received clearance of its Investigational New Drug Application (“IND”) from the U.S. Food and Drug Administration (“FDA”) to initiate a first-in-human Phase 1 dose escalation clinical trial to evaluate one of its lead drug candidates, HCW9302, in patients with moderate-to-severe alopecia areata, a common autoimmune disease in humans that currently has no curative FDA approved treatments.
globenewswire.com
- 1 month ago
HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025
MIRAMAR, Fla., Jan. 15, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic inflammation and disease, announced today that Hing C.
globenewswire.com
- 2 months ago
HCW Biologics Inc. Received NASDAQ Staff Determination Letter
Company Expected Notice for Continued Deficiency and Delist Letter from the Nasdaq Stock Market Company Intends to Request Hearing to Appeal in a Timely Manner MIRAMAR, Fla., Dec. 23, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported on December 17, 2024, the Company received written notice from the Listing Qualifications Staff (“Staff”) that it had failed to re-gain compliance for continued listing requirements of the Nasdaq Global Markets.
globenewswire.com
- 3 months ago
HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules
MIRAMAR, Fla., Nov. 18, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 6,717,000 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced above market under Nasdaq rules.
globenewswire.com
- 4 months ago
Why Is Penny Stock HCW Biologics Surging On Monday?
HCW Biologics Inc HCWB stock is trading higher during Monday premarket with a strong session volume of 10.03 million versus an average volume of 48.02K, as per data from Benzinga Pro.
benzinga.com
- 4 months ago
HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate
HCW Biologics entered into License, Research and Co-Development Agreement with WY Biotech for one of its new proprietary preclinical molecules HCW Biologics to receive upfront payment of $7 million and is eligible to receive additional milestone payments and double-digit royalties on future product sales MIRAMAR, Fla., Nov. 18, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, and WY Biotech Co., Ltd.
globenewswire.com
- 4 months ago
HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights
MIRAMAR, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its third quarter ended September 30, 2024.
globenewswire.com
- 4 months ago
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction
This release has made a correction to a release issued under the same headline on August 14, 2024, by HCW Biologics, Inc. (NASDAQ: HCWB), to show the amount included in the condensed interim balance sheet for Cash and cash equivalents as of December 31, 2023 as $3,595,101, not $95,101 as previously stated. The full text of the corrected release is as follows: MIRAMAR, Fla.
globenewswire.com
- 7 months ago
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights
MIRAMAR, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2024.
globenewswire.com
- 7 months ago
HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights
MIRAMAR, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2024.
globenewswire.com
- 10 months ago
HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights
MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023.
globenewswire.com
- 1 year ago
8. Profile
Summary
HCW Biologics Inc. HCWB
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 12.7 M
Dividend Yield
0.00%
Description
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
Contact
2929 North Commerce Parkway, Miramar, FL, 33025
https://www.hcwbiologics.com
IPO
Date
July 20, 2021
Employees
45
Officers
Ms. Rebecca Byam CPA, M.B.A.
Chief Financial Officer
Ms. Nicole Valdivieso Esq.
Vice President of Legal Affairs
Mr. Lee D. Flowers
Senior Vice President of Business Development
Dr. Hing C. Wong Ph.D.
Founder, Chief Executive Officer, Director & Secretary
Dr. Peter Rhode Ph.D.
Chief Scientific Officer & Vice President of Clinical Operations